Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.

Article  PubMed  Google Scholar 

Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212–24.

Article  CAS  PubMed  Google Scholar 

Liver EAftSot. European association for the study of diabetes (EASD) European association for the study of obesity (EASO) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.

Article  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16(6):377–86.

Article  PubMed  Google Scholar 

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904.

Article  PubMed  Google Scholar 

Estes C, Chan HL, Chien RN, Chuang WL, Fung J, Goh GB-B, et al. Modelling NAFLD disease burden in four Asian regions—2019-2030. Aliment Pharmacol Ther. 2020;51(8):801–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020;69(9):1691–705.

Article  CAS  PubMed  Google Scholar 

Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13(5):1000–8. e3.

Article  CAS  PubMed  Google Scholar 

Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, et al. Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health. 2019;16(17):3104.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ismaiel A, Dumitraşcu DL. Cardiovascular risk in fatty liver disease: the liver-heart axis—literature review. Front Med. 2019;6:202.

Article  Google Scholar 

Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a key player in the crosstalk between inflammation and cardiovascular diseases. Int J Mol Sci. 2019;20(7):1599.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solano-Urrusquieta A, Morales-González JA, Castro-Narro GE, Cerda-Reyes E, Flores-Rangel PD, Fierros-Oceguera R. NRF-2 and nonalcoholic fatty liver disease. Ann Hepatol. 2020;19(5):458–65.

Article  CAS  PubMed  Google Scholar 

Gao W, Wang D, Shi Y, Sun Y, Deng J, Song X, et al. Potential cardiovascular disease treatment by natural drugs targeting the HIF-1α factor and its pathway. Combinatorial Chemistry & High Throughput Screening; 2024.

Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan Y-T, et al. Divergent TNF receptor-related remodeling responses in heart failure: role of NF-κB and inflammatory activation. Circulation. 2009;119(10):1386.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev. 2016;21(2):169–76.

Article  CAS  PubMed  Google Scholar 

Zhang Y-J, Gan R-Y, Li S, Zhou Y, Li A-N, Xu D-P, et al. Antioxidant phytochemicals for the prevention and treatment of chronic diseases. Molecules. 2015;20(12):21138–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayat E, Rahpeima Z, Dastghaib S, Gholizadeh F, Erfani M, Asadikaram G, et al. Stevia rebaudiana extract attenuate metabolic disorders in diabetic rats via modulation of glucose transport and antioxidant signaling pathways and aquaporin-2 expression in two extrahepatic tissues. J Food Biochem. 2020;44(8):e13252.

Article  CAS  PubMed  Google Scholar 

Moradi Mn, Behrouj H, Alipoor B, Kheiripour N, Ghasemi H, Ghasemi H. Chlorella vulgaris is an effective supplement in counteracting non-alcoholic fatty liver disease‐related complications through modulation of dyslipidemia, insulin resistance, and inflammatory pathways. J Food Biochem. 2021;45(10):e13914.

PubMed  Google Scholar 

Yarmohammadi S, Hosseini-Ghatar R, Foshati S, Moradi M, Hemati N, Moradi S, et al. Effect of chlorella vulgaris on liver function biomarkers: a systematic review and meta-analysis. Clin Nutr Res. 2021;10(1):83.

Article  PubMed  PubMed Central  Google Scholar 

Albillos A, De Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–77.

Article  CAS  PubMed  Google Scholar 

Song Q, Zhang X. The role of gut–liver axis in gut microbiome dysbiosis associated NAFLD and NAFLD-HCC. Biomedicines. 2022;10(3):524.

Article  PubMed  PubMed Central  Google Scholar 

Stavropoulou E, Bezirtzoglou E. Probiotics in medicine: a long debate. Front Immunol. 2020;11:2192.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang K, Song M. New insights into the pathogenesis of metabolic-associated fatty liver disease (MAFLD): gut–liver–heart crosstalk. Nutrients. 2023;15(18):3970.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hill D, Sugrue I, Tobin C, Hill C, Stanton C, Ross RP. The Lactobacillus casei group: history and health related applications. Front Microbiol. 2018;9:2107.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Zhou H, Zhou X, Sun J, Liang X, Lv Y, et al. Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway. Br J Nutr. 2021;125(5):521–9.

Article  CAS  PubMed  Google Scholar 

Zhang Z, Zhou H, Guan M, Zhou X, Liang X, Lv Y, et al. Lactobacillus casei YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice. Br J Nutr. 2021;125(10):1081–91.

Article  CAS  PubMed  Google Scholar 

Keyghobadi H, Bozorgpoursavadjani H, Koohpeyma F, Mohammadipoor N, Nemati M, Dehghani F, et al. Therapeutic potential of Lactobacillus casei and chlorella vulgaris in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD)-associated kidney damages: a stereological study. Mol Biol Rep. 2024;51(1):613.

Article  CAS  PubMed  Google Scholar 

Panahi Y, Ghamarchehreh ME, Beiraghdar F, Zare R, Jalalian HR, Sahebkar A. Investigation of the effects of chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial. Hepatogastroenterology. 2012;59(119):2099–103.

PubMed  Google Scholar 

Cho J, Lee I, Kim D, Koh Y, Kong J, Lee S, et al. Effect of aerobic exercise training on non-alcoholic fatty liver disease induced by a high fat diet in C57BL/6 mice. J Exerc Nutrition Biochem. 2014;18(4):339.

Article  PubMed  PubMed Central  Google Scholar 

An H-J, Choi H-M, Park H-S, Han J-G, Lee E-H, Park Y-S, et al. Oral administration of hot water extracts of chlorella vulgaris increases physical stamina in mice. Ann Nutr Metab. 2006;50(4):380–6.

Article  CAS  PubMed  Google Scholar 

Naderi-Boldaji V, Joukar S, Noorafshan A, Raji-Amirhasani A, Naderi-Boldaji S, Bejeshk M-a. The effect of blood flow restriction along with low-intensity exercise on cardiac structure and function in aging rat: role of angiogenesis. Life Sci. 2018;209:202–9.